Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

January 4, 2022
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com
Media Inquiries:
Meichiel Keenan
Public Affairs
mkeenan@fibrogen.com

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
Contact Us

Focus Areas

Our Expertise
Anemia
Idiopathic Pulmonary Fibrosis
Pancreatic Cancer
Duchenne Muscular Dystrophy
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Notice

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2022 FibroGen, Inc.
409 Illinois Street, San Francisco, CA 94158